thirty-six neuroleptic-treated patients underwent a placebo-controlled acute iv challenge with 2 mg benztropine and a placebo-controlled two-week trial of oral benztropine mesylate ( 2 mg three times a day ) , followed by a double-blind placebo-controlled neuroleptic withdrawal involving four weeks of dose tapering and six weeks of placebo treatment .
C0005098
benztropine
C0053156
benztropine mesylate